Financial Information
This section of the Karyopharm Therapeutics InvestorRoom houses up to date financial reporting information and interactive tools to provide you with the resources you need to manipulate and understand our current financial standing.
Please note: All data in this section is provided by a 3rd party provider and may be delayed up to 20 minutes. Karyopharm Therapeutics assumes no responsibility for the accuracy of this data and provides it for informational purposes only.
NASDAQKPTI
| Beta | 0.20 |
|---|---|
| Shares Outstanding | 75.5M |
| Average Volume (10 days) | 1.6M |
| Qtrly Dividend (Ann. Yield) | -- (--) |
Analyst Views
| Current Mean Recommendation | Buy |
|---|
| Strong Buy | 3 | |
|---|---|---|
| Buy | 1 | |
| Hold | 3 | |
| Underperform | 0 | |
| Sell | 1 |
Recent Insider Transactions
Jatin Shah EVP, Chief Medical Officer | (665) Dispose Jul 12, 2021 |
|---|---|
Sohanya Roshan Cheng SVP Sales & Commercial Ops | 7,500 Acquire Jun 30, 2021 |
Stephen Mitchener SVP, Chief Business Officer | (528) Sell Jun 2, 2021 |
Jatin Shah EVP, Chief Medical Officer | 23,250 Buy May 7, 2021 |
Garen G. Bohlin Director | 4,000 Buy May 6, 2021 |